<?xml version="1.0" encoding="UTF-8"?>
<p id="p0020">On March 16, 2020, a controversial French researcher associated with a significant prior publication scandal (
 <xref rid="bib1" ref-type="bibr">1</xref>) announced via an Internet video posting that he and his team had experienced success in treating 24 COVID-19 patients with a combination of hydroxychloroquine and azithromycin (
 <xref rid="bib2" ref-type="bibr">2</xref>). A few days later, President Trump touted the drug as a virtually risk-free cure to COVID, asking rhetorically, “what do you have to lose?” (
 <xref rid="bib3" ref-type="bibr">3</xref>). An almost immediate shortage of hydroxychloroquine resulted as the U.S. government stockpiled the drug, doctors began prescribing it off-label, and some patients began hoarding. Patients who needed hydroxychloroquine for its proven indications began to run out.
</p>
